EuroCetus B.V., a unit of Chiron Corp., on Thursday said that ithas received regulatory approval to market Proleukininterleukin-2 to treat metastatic renal cell carcinoma inAustria.
EuroCetus said it will start distributing the drug immediately.The company is currently marketing Proleukin for treatment ofthe disease in 11 European countries: Germany, Denmark, theNetherlands, Ireland, Italy, Spain, France, the United Kingdom,Belgium, Luxembourg and the former Soviet Union.
Shares of the Emeryville, Calif., parent company (NASDAQ:CHIR)gained $1.50 to $43.25.
(c) 1997 American Health Consultants. All rights reserved.